Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.61 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15239406 | 1.00 | FFAR1 (0.61) | FFAR1DEGS1HDAC4KDM1AALDH1A1 | |
| SCHEMBL22466332 | 1.00 | FFAR1 (0.61) | FFAR1DEGS1HDAC4KDM1AALDH1A1 | |
| SCHEMBL22466320 | 1.00 | FFAR1 (0.61) | FFAR1DEGS1HDAC4KDM1AALDH1A1 | |
| SCHEMBL15239255 | 1.00 | FFAR1 (0.61) | FFAR1DEGS1HDAC4KDM1AALDH1A1 | |
| SCHEMBL14244532 | 1.00 | FFAR1 (0.61) | FFAR1DEGS1HDAC4KDM1AALDH1A1 | |
| SCHEMBL2034678 | 0.83 | FFAR1 (0.70) | FFAR1DEGS1HDAC4ALDH1A1SLC9A1 | |
| SCHEMBL323824 | 0.83 | FFAR1 (0.70) | FFAR1DEGS1HDAC4ALDH1A1SLC9A1 | |
| SCHEMBL4126470 | 0.83 | FFAR1 (0.70) | FFAR1DEGS1HDAC4ALDH1A1SLC9A1 | |
| SCHEMBL5217474 | 0.83 | FFAR1 (0.70) | FFAR1DEGS1HDAC4ALDH1A1SLC9A1 | |
| SCHEMBL8295172 | 0.83 | FFAR1 (0.70) | FFAR1DEGS1HDAC4ALDH1A1SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585749-B1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1585749-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2005-10-19 | — | — | EP | claimed |
| WO-2004063198-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2004-07-29 | — | — | WO | claimed |
| CN-113614089-B | Morphinans useful in the treatment of medical conditions | 人福医药美国公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20220089605-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-20220089605-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2022-03-24 | — | — | US | disclosed |
| US-11214577-B2 | Morphinans useful for treating medical disorders | Humanwell Pharmaceutical US (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | SANTOLECAN PHARMACEUTICALS LLC | 2021-07-29 | — | — | US | disclosed |
| EP-3812376-A1 | PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Santolecan Pharmaceuticals LLC (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2020205735-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | Humanwell Pharmaceutical US (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20200308185-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | AGOURON PHARMACEUTICALS, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7132533-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| US-6967198-B2 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS INC. (US) | 2005-11-22 | — | — | US | disclosed |
| EP-1585749-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | AGOURON PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2004063198-A1 | DIAZEPINOINDOLE DERIVATIVES AS KINASE INHIBITORS | PFIZER INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004052-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK1, CHEK2, CHKA | FFAR1 3443/4885DEGS1 1893/4885HDAC4 929/4885 |
| US-20210228530-A1 | TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF | DDOST, UGT2B17, UGT1A7 | FFAR1 1687/4885DEGS1 765/4885HDAC4 1441/4885 |
| US-20050075499-A1 | Tricyclic compounds protein kinase inhibitors for enhancing the efficacy of anti-neoplastic agents and radiation therapy | CHEK2, CHEK1, CHKA | FFAR1 3329/4885DEGS1 1933/4885HDAC4 930/4885 |
| US-20200308185-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | OPRK1, OPRM1, OPRL1 | FFAR1 320/4885DEGS1 3572/4885HDAC4 3582/4885 |
| US-11214577-B2 | Morphinans useful for treating medical disorders | OPRM1, OPRL1, OPRK1 | FFAR1 359/4885DEGS1 2598/4885HDAC4 3806/4885 |
| US-20070135415-A1 | TRICYCLIC COMPOUNDS PROTEIN KINASE INHIBITORS FOR ENHANCING THE EFFICACY OF ANTI-NEOPLASTIC AGENTS AND RADIATION THERAPY | CHEK1, CHEK2, CHKA | FFAR1 3275/4885DEGS1 1858/4885HDAC4 970/4885 |
| US-20220089605-A1 | NOVEL MORPHINANS USEFUL FOR TREATING MEDICAL DISORDERS | OPRK1, OPRM1, OPRL1 | FFAR1 320/4885DEGS1 3572/4885HDAC4 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.